Study Title: A Phase 1 Study of the SHP2 Inhibitor BBP 398 (formerly known as IACS 15509) in Combination with the Programmed Death Receptor 1 Blocking Antibody Nivolumab in Patients with Advanced Non Small Cell Lung Cancer with a KRAS Mutation
For more information about the trial above please contact the study team: